{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:07:13Z","timestamp":1787047633657,"version":"build-2736575974"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T00:00:00Z","timestamp":1665792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T00:00:00Z","timestamp":1665792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psoriatic arthritis (PsA) is a heterogeneous chronic musculoskeletal disease, affecting up to 30% of people with psoriasis. Research into PsA pathogenesis has led to the development of targeted therapies, including Tumor Necrosis Factor inhibitors (TNF-i). Good response is only achieved by ~60% of patients leading to \u2018trial and error\u2019 drug management approaches, adverse reactions and increasing healthcare costs. Robust and well-validated biomarker identification, and subsequent development of sensitive and specific assays, would facilitate the implementation of a stratified approach into clinical care. This review will summarise potential genetic biomarkers for TNF-i (adalimumab, etanercept and infliximab) response that have been reported to date. It will also comment upon the importance of managing clinical confounders when understanding drug response prediction. Variants in multiple gene regions including<jats:italic>TNF-A, FCGR2A, TNFAIP3, TNFR1\/TNFR1A\/TNFRSF1A, TRAIL-R1\/TNFRSF10A, FCGR3A<\/jats:italic>have been reported to correlate with TNF-i response at various levels of statistical significance in patients with PsA. However, results were often from heterogenous and underpowered cohorts and none are currently implemented into clinical practice. External validation of genetic biomarkers in large, well-documented cohorts is required, and assessment of the predictive value of combining multiple genetic biomarkers with clinical measures is essential to clinically embed pharmacogenomics into PsA drug management.<\/jats:p>","DOI":"10.1038\/s41397-022-00290-8","type":"journal-article","created":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T05:02:45Z","timestamp":1665810165000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0013-460X","authenticated-orcid":false,"given":"Philippa D. K.","family":"Curry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3316-2527","authenticated-orcid":false,"given":"Anne","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5062-5779","authenticated-orcid":false,"given":"James","family":"Bluett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,15]]},"reference":[{"key":"290_CR1","doi-asserted-by":"publisher","first-page":"108318","DOI":"10.1016\/j.clim.2019.108318","volume":"211","author":"J Pouw","year":"2020","unstructured":"Pouw J, Leijten E, Radstake T, Boes M. Emerging molecular biomarkers for predicting therapy response in psoriatic arthritis: A review of literature. Clin Immunol. 2020;211:108318.","journal-title":"Clin Immunol"},{"key":"290_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.12659\/PJR.883763","volume":"78","author":"AJ Sankowski","year":"2013","unstructured":"Sankowski AJ, \u0141ebkowska UM, \u0106wik\u0142a J, Walecka I, Walecki J. Psoriatic arthritis. Pol J Radio. 2013;78:7\u201317.","journal-title":"Pol J Radio"},{"key":"290_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JMH Moll","year":"1973","unstructured":"Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55\u201378.","journal-title":"Semin Arthritis Rheum"},{"key":"290_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/ard.32.3.181","volume":"32","author":"JMH Moll","year":"1973","unstructured":"Moll JMH, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis. 1973;32:181\u2013201.","journal-title":"Ann Rheum Dis"},{"key":"290_CR5","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1396-0296.2004.04038.x","volume":"17","author":"DD Gladman","year":"2017","unstructured":"Gladman DD. Psoriatic arthritis. Dermatol Ther. 2017;17:350\u201363.","journal-title":"Dermatol Ther"},{"key":"290_CR6","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","volume":"42","author":"D Kane","year":"2003","unstructured":"Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatol (Oxf). 2003;42:1460\u20138.","journal-title":"Rheumatol (Oxf)"},{"key":"290_CR7","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2340\/00015555-1833","volume":"94","author":"K de Vlam","year":"2014","unstructured":"de Vlam K, Gottlieb AB, Mease PJ, Mease PJ. Current concepts in psoriatic arthritis: Pathogenesis and management. Acta Derm-Venereol. 2014;94:627\u201334.","journal-title":"Acta Derm-Venereol"},{"key":"290_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS. Psoriatic arthritis: State of the art review. Clin Med (Lond). 2017;17:65\u201370.","journal-title":"Clin Med (Lond)"},{"key":"290_CR9","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1080\/09546634.2019.1605142","volume":"31","author":"A Gottlieb","year":"2020","unstructured":"Gottlieb A, Merola JF. Psoriatic arthritis for dermatologists. J Dermatol Treat. 2020;31:662\u201379.","journal-title":"J Dermatol Treat"},{"key":"290_CR10","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/rheumatology\/keq131","volume":"49","author":"SMM Verstappen","year":"2010","unstructured":"Verstappen SMM, Watson KD, Lunt M, McGrother K, Symmons DPM, Hyrich KL. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: Results from the British Society for Rheumatology Biologics Register. Rheumatol (Oxf). 2010;49:1570\u20137.","journal-title":"Rheumatol (Oxf)"},{"key":"290_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13075-021-02417-x","volume":"23","author":"A Haddad","year":"2021","unstructured":"Haddad A, Gazitt T, Feldhamer I, Feld J, Cohen A, Lavi I, et al. Treatment persistence of biologics among patients with psoriatic arthritis. Arthritis Res Ther. 2021;23:44.","journal-title":"Arthritis Res Ther"},{"key":"290_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/BOR.0000000000000152","volume":"27","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015;27:118\u201326.","journal-title":"Curr Opin Rheumatol"},{"key":"290_CR13","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3899\/jrheum.130457","volume":"40","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Gelfand JM, Boehncke WH, Armstrong EJ. Cardiovascular comorbidities of psoriasis and psoriatic arthritis: A report from the GRAPPA 2012 annual meeting. J Rheumatol. 2013;40:1434\u20137.","journal-title":"J Rheumatol"},{"key":"290_CR14","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1001\/archderm.1997.03890470143031","volume":"133","author":"PA Klein","year":"1997","unstructured":"Klein PA, Greene WH, Fuhrer J, Clark RA. Prevalence of methicillin-resistant Staphylococcus aureus in outpatients with psoriasis, atopic dermatitis, or HIV infection. Arch Dermatol. 1997;133:1463\u20135.","journal-title":"Arch Dermatol"},{"key":"290_CR15","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00296-017-3873-4","volume":"38","author":"T Thrastardottir","year":"2018","unstructured":"Thrastardottir T, Love TJ. Infections and the risk of psoriatic arthritis among psoriasis patients: A systematic review. Rheumatol Int. 2018;38:1385\u201397.","journal-title":"Rheumatol Int"},{"key":"290_CR16","first-page":"2167","volume":"33","author":"C Han","year":"2006","unstructured":"Han C, Robinson DWJ, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33:2167\u201372.","journal-title":"J Rheumatol"},{"key":"290_CR17","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1136\/ard.2008.094839","volume":"68","author":"DD Gladman","year":"2009","unstructured":"Gladman DD, Ang M, Su L, Tom BDM, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009;68:1131\u20135.","journal-title":"Ann Rheum Dis"},{"key":"290_CR18","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/art.1780401021","volume":"40","author":"K Wong","year":"1997","unstructured":"Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: Results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997;40:1868\u201372.","journal-title":"Arthritis Rheum"},{"key":"290_CR19","doi-asserted-by":"crossref","first-page":"e12946","DOI":"10.1111\/sji.12946","volume":"92","author":"LL Ten Bergen","year":"2020","unstructured":"Ten Bergen LL, Petrovic A, Krogh Aarebrot A, Appel S. The TNF\/IL-23\/IL-17 axis\u2014Head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020;92:e12946.","journal-title":"Scand J Immunol"},{"key":"290_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","volume":"18","author":"G Schett","year":"2022","unstructured":"Schett G, Rahman P, Ritchlin C, McInnes IB, Elewaut D, Scher JU. Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol. 2022;18:311\u201325.","journal-title":"Nat Rev Rheumatol"},{"key":"290_CR21","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/17512433.2017.1329009","volume":"10","author":"S Mantravadi","year":"2017","unstructured":"Mantravadi S, Ogdie A, Kraft WK. Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharm. 2017;10:899\u2013910.","journal-title":"Expert Rev Clin Pharm"},{"key":"290_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11926-015-0518-z","volume":"17","author":"M Jani","year":"2015","unstructured":"Jani M, Barton A, Ho P. Pharmacogenetics of Treatment Response in Psoriatic Arthritis. Curr Rheumatol Rep. 2015;17:44.","journal-title":"Curr Rheumatol Rep"},{"key":"290_CR23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrrheum.2014.106","volume":"10","author":"I Olivieri","year":"2014","unstructured":"Olivieri I, D\u2019Angelo S, Palazzi C, Padula A. Advances in the management of psoriatic arthritis. Nat Rev Rheumatol. 2014;10:531\u201342.","journal-title":"Nat Rev Rheumatol"},{"key":"290_CR24","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.semarthrit.2016.09.005","volume":"46","author":"K Aaltonen","year":"2017","unstructured":"Aaltonen K, Heinonen A, Joensuu J, Parmanne P, Karjalainen A, Varjolahti-Lehtinen T, et al. Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study. Semin Arthritis Rheum. 2017;46:732\u20139.","journal-title":"Semin Arthritis Rheum"},{"key":"290_CR25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40273-018-0618-5","volume":"36","author":"LS D\u2019Angiolella","year":"2018","unstructured":"D\u2019Angiolella LS, Cortesi PA, Lafranconi A, Micale M, Mangano S, Cesana G, et al. Cost and cost effectiveness of treatments for psoriatic arthritis: A systematic literature review. Pharmacoeconomics 2018;36:567\u201389.","journal-title":"Pharmacoeconomics"},{"key":"290_CR26","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s10067-017-3636-3","volume":"36","author":"S Schwartzman","year":"2017","unstructured":"Schwartzman S, Li Y, Zhou H, Palmer JB. Economic impact of biologic utilization patterns in patients with psoriatic arthritis. Clin Rheumatol. 2017;36:1579\u201388.","journal-title":"Clin Rheumatol"},{"key":"290_CR27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.berh.2019.03.001","volume":"32","author":"O FitzGerald","year":"2018","unstructured":"FitzGerald O, Ritchlin C. Opportunities and challenges in the treatment of psoriatic arthritis. Best Pr Res Clin Rheumatol. 2018;32:440\u201352.","journal-title":"Best Pr Res Clin Rheumatol"},{"key":"290_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40268-017-0215-7","volume":"17","author":"L Costa","year":"2017","unstructured":"Costa L, Perricone C, Chimenti MS, Del Puente A, Caso P, Peluso R, et al. Switching between biological treatments in psoriatic arthritis: A review of the evidence. Drugs R D. 2017;17:509\u201322.","journal-title":"Drugs R D"},{"key":"290_CR29","doi-asserted-by":"publisher","first-page":"862969","DOI":"10.1155\/2014\/862969","volume":"2014","author":"M Fabbroni","year":"2014","unstructured":"Fabbroni M, Cantarini L, Caso F, Costa L, Pagano VA, Frediani B, et al. Drug retention rates and treatment discontinuation among anti-TNF- \u03b1 agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm. 2014;2014:862969.","journal-title":"Mediators Inflamm"},{"key":"290_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/art.30117","volume":"63","author":"B Glintborg","year":"2011","unstructured":"Glintborg B, \u00c3stergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy: Results from the nationwide Danish DANBIO registry. Arthritis Rheum. 2011;63:382\u201390.","journal-title":"Arthritis Rheum"},{"key":"290_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2670","volume":"11","author":"AA Saad","year":"2009","unstructured":"Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DPM. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: Observational study from the British Society of rheumatology biologics register. Arthritis Res Ther. 2009;11:1\u20139.","journal-title":"Arthritis Res Ther"},{"key":"290_CR32","doi-asserted-by":"publisher","first-page":"956","DOI":"10.7326\/0003-4819-118-12-199306150-00008","volume":"118","author":"E Ernst","year":"1993","unstructured":"Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor. Ann Intern Med. 1993;118:956\u201363.","journal-title":"Ann Intern Med"},{"key":"290_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/tpj.2017.31","volume":"18","author":"ND Loft","year":"2018","unstructured":"Loft ND, Skov L, Iversen L, Gniadecki R, Dam TN, Brandslund I, et al. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. Pharmacogenomics J. 2018;18:494\u2013500.","journal-title":"Pharmacogenomics J"},{"key":"290_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/ard.40.1.66","volume":"40","author":"MR Laurent","year":"1981","unstructured":"Laurent MR, Panayi GS, Shepherd P. Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis. 1981;40:66\u20139.","journal-title":"Ann Rheum Dis"},{"key":"290_CR35","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/0190-9622(95)91336-X","volume":"32","author":"T Henseler","year":"1995","unstructured":"Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32:982\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"290_CR36","first-page":"55","volume":"42","author":"PD Carvalho","year":"2017","unstructured":"Carvalho PD, Duarte C, Vieira-Sousa E, Cunha-Miranda L, Avila-Ribeiro P, Santos H, et al. Predictors of response to TNF blockers in patients with polyarticular psoriatic arthritis. Acta Reumatol Port. 2017;42:55\u201365.","journal-title":"Acta Reumatol Port"},{"key":"290_CR37","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/bjd.13091","volume":"171","author":"S Kusumoto","year":"2014","unstructured":"Kusumoto S, Kajihara I, Nagamoto E, Makino K, Ichihara A, Aoi J, et al. Increased CCL22 expression in psoriatic skin predicts a good response to infliximab therapy. Br J Dermatol. 2014;171:1259\u201361.","journal-title":"Br J Dermatol"},{"key":"290_CR38","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/rheumatology\/keq091","volume":"49","author":"L Eder","year":"2010","unstructured":"Eder L, Chandran V, Schentag CT, Shen H, Cook RJ, Gladman DD. Time and predictors of response to tumour necrosis factor-\u03b1 blockers in psoriatic arthritis: An analysis of a longitudinal observational cohort. Rheumatol (Oxf). 2010;49:1361\u20136.","journal-title":"Rheumatol (Oxf)"},{"key":"290_CR39","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1093\/rheumatology\/keaa780","volume":"60","author":"C Ballegaard","year":"2021","unstructured":"Ballegaard C, Skougaard M, Guldberg-M\u00f8ller J, Nissen CV, Amris K, J\u00f8rgensen TS, et al. Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study. Rheumatol (Oxf). 2021;60:3289\u20133300.","journal-title":"Rheumatol (Oxf)"},{"key":"290_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/PSY.0b013e3181907c1b","volume":"71","author":"MB Howren","year":"2009","unstructured":"Howren MB, Lamkin DM, Suls J. Associations of depression with c-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom Med. 2009;71:171\u201386.","journal-title":"Psychosom Med"},{"key":"290_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.semarthrit.2017.03.008","volume":"47","author":"F Cantini","year":"2017","unstructured":"Cantini F, Niccoli L, Nannini C, Cassar\u00e0 E, Kaloudi O, Giulio Favalli E, et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum. 2017;47:183\u201392.","journal-title":"Semin Arthritis Rheum"},{"key":"290_CR42","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3899\/jrheum.170477","volume":"45","author":"ID Flouri","year":"2018","unstructured":"Flouri ID, Markatseli TE, Boki KA, Papadopoulos I, Skopouli FN, Voulgari PV, et al. Comparative analysis and predictors of 10-year tumor necrosis factor inhibitors drug survival in patients with spondyloarthritis: First-year response predicts longterm drug persistence. J Rheumatol. 2018;45:785\u201394.","journal-title":"J Rheumatol"},{"key":"290_CR43","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3899\/jrheum.171034","volume":"46","author":"A Ogdie","year":"2019","unstructured":"Ogdie A, Palmer JL, Greenberg J, Curtis JR, Harrold LR, Solomon DH, et al. Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitor. J Rheumatol. 2019;46:475\u201382.","journal-title":"J Rheumatol"},{"key":"290_CR44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/acr.21711","volume":"65","author":"M Nicola","year":"2013","unstructured":"Nicola M, Di D, Peluso R, Iervolino S, Lupoli R, Russolillo A, et al. Obesity and the prediction of minimal disease activity: A prospective study in psoriatic. Arthritis Care Res (Hoboken). 2013;65:141\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"290_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3109\/03009742.2012.715186","volume":"42","author":"F Iannone","year":"2013","unstructured":"Iannone F, Fanizzi R, Scioscia C, Anelli MG, Lapadula G. Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-\u03b1 therapy. Scand J Rheumatol. 2013;42:41\u20134.","journal-title":"Scand J Rheumatol"},{"key":"290_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Singh AG, Casteele NV, Zarrinpar A, Prokop LG. et al. Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One. 2018;13:1\u201326.","journal-title":"PLoS One"},{"key":"290_CR47","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/ijo.2015.64","volume":"39","author":"S Upala","year":"2015","unstructured":"Upala S, Sanguankeo A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: A systematic review and meta-analysis. Int J Obes (Lond). 2015;39:1197\u2013202.","journal-title":"Int J Obes (Lond)"},{"key":"290_CR48","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","volume":"73","author":"MND Di Minno","year":"2014","unstructured":"Di Minno MND, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b1 blockers. Ann Rheum Dis. 2014;73:1157\u201362.","journal-title":"Ann Rheum Dis"},{"key":"290_CR49","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s10067-017-3593-x","volume":"36","author":"LR Harrold","year":"2017","unstructured":"Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, et al. Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry. Clin Rheumatol. 2017;36:895\u2013901.","journal-title":"Clin Rheumatol"},{"key":"290_CR50","doi-asserted-by":"publisher","first-page":"108397","DOI":"10.1016\/j.clim.2020.108397","volume":"214","author":"LM Perez-Chada","year":"2020","unstructured":"Perez-Chada LM, Merola JF. Comorbidities associated with psoriatic arthritis: Review and update. Clin Immunol. 2020;214:108397.","journal-title":"Clin Immunol"},{"key":"290_CR51","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1007\/s10067-021-05742-3","volume":"40","author":"M Pombo-Suarez","year":"2021","unstructured":"Pombo-Suarez M, Sanchez-Piedra C, Garcia-Magall\u00f3n B, P\u00e9rez-G\u00f3mez A, Manrique-Arija S, Mart\u00edn-Dom\u00e9nech R, et al. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry. Clin Rheumatol. 2021;40:3979\u201388.","journal-title":"Clin Rheumatol"},{"key":"290_CR52","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00296-019-04416-3","volume":"40","author":"EG Favalli","year":"2020","unstructured":"Favalli EG, Becciolini A, Carletto A, Conti F, Amato G, Fusaro E, et al. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort. Rheumatol Int. 2020;40:263\u201372.","journal-title":"Rheumatol Int"},{"key":"290_CR53","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3899\/jrheum.190253","volume":"47","author":"M Jani","year":"2020","unstructured":"Jani M, Chinoy H, Barton A. Association of pharmacological biomarkers with treatment response and longterm disability in patients with psoriatic arthritis: Results from OUTPASS. J Rheumatol. 2020;47:1204\u20138.","journal-title":"J Rheumatol"},{"key":"290_CR54","doi-asserted-by":"publisher","first-page":"R105","DOI":"10.1186\/ar3386","volume":"13","author":"E Ducourau","year":"2011","unstructured":"Ducourau E, Mulleman D, Paintaud G, Miow Lin DC, Lauf\u00e9ron F, Ternant D, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011;13:R105.","journal-title":"Arthritis Res Ther"},{"key":"290_CR55","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cyto.2018.08.025","volume":"111","author":"K Furue","year":"2018","unstructured":"Furue K, Ito T, Furue M. Differential efficacy of biologic treatments targeting the TNF-\u03b1\/IL-23\/IL-17 axis in psoriasis and psoriatic arthritis. Cytokine 2018;111:182\u20138.","journal-title":"Cytokine"},{"key":"290_CR56","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s10067-013-2336-x","volume":"32","author":"CC Mok","year":"2013","unstructured":"Mok CC, Van Der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNF\u03b1 biologics in rheumatic diseases. Clin Rheumatol. 2013;32:1429\u201335.","journal-title":"Clin Rheumatol"},{"key":"290_CR57","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/17425247.2020.1736552","volume":"17","author":"BPH Pouls","year":"2020","unstructured":"Pouls BPH, Kristensen LE, Petersson M, van den Bemt BJF, Ballerini L, Bruggraber R, et al. A pilot study examining patient preference and satisfaction for ava\u00ae, a reusable electronic injection device to administer certolizumab pegol. Expert Opin Drug Deliv. 2020;17:705\u201311.","journal-title":"Expert Opin Drug Deliv"},{"key":"290_CR58","first-page":"213","volume":"59","author":"HF Hope","year":"2020","unstructured":"Hope HF, Hyrich KL, Anderson J, Bluett J, Sergeant JC, Barton A, et al. The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate. Rheumatol (Oxf). 2020;59:213\u201323.","journal-title":"Rheumatol (Oxf)"},{"key":"290_CR59","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/rheumatology\/keu358","volume":"54","author":"J Bluett","year":"2015","unstructured":"Bluett J, Morgan C, Thurston L, Plant D, Hyrich KL, Morgan AW, et al. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: Results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatol (Oxf). 2015;54:494\u20139.","journal-title":"Rheumatol (Oxf)"},{"key":"290_CR60","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","volume":"143","author":"N Dand","year":"2019","unstructured":"Dand N, Duckworth M, Baudry D, Russell A, Curtis CJ, Lee SH, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143:2120\u201330.","journal-title":"J Allergy Clin Immunol"},{"key":"290_CR61","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2217\/pgs.16.20","volume":"94","author":"R Cascella","year":"2016","unstructured":"Cascella R, Strafella C, Longo G, MacCarone M, Borgiani P, Sangiuolo F, et al. Pharmacogenomics of multifactorial diseases: A focus on psoriatic arthritis. Pharmacogenomics 2016;94:943\u201351.","journal-title":"Pharmacogenomics"},{"key":"290_CR62","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s12016-012-8303-5","volume":"44","author":"V Chandran","year":"2013","unstructured":"Chandran V. The genetics of psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44:149\u201356.","journal-title":"Clin Rev Allergy Immunol"},{"key":"290_CR63","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1038\/jid.2014.123","volume":"134","author":"G Murdaca","year":"2014","unstructured":"Murdaca G, Gulli R, Span\u00f2 F, Lantieri F, Burlando M, Parodi A, et al. TNF-\u03b1 gene polymorphisms: Association with disease susceptibility and response to anti-TNF-\u03b1 treatment in psoriatic arthritis. J Invest Dermatol. 2014;134:2503\u20139.","journal-title":"J Invest Dermatol"},{"key":"290_CR64","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2217\/14622416.9.2.195","volume":"9","author":"P Rahman","year":"2008","unstructured":"Rahman P, O\u2019Rielly DD. Psoriatic arthritis: Genetic susceptibility and pharmacogenetics. Pharmacogenomics 2008;9:195\u2013205.","journal-title":"Pharmacogenomics"},{"key":"290_CR65","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/rheumatology\/kel175","volume":"46","author":"M Seitz","year":"2007","unstructured":"Seitz M, Wirthm\u00fcller U, M\u00f6ller B, Villiger PM. The -308 tumour necrosis factor-\u03b1 gene polymorphism predicts therapeutic response to TNF\u03b1-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatol (Oxf). 2007;46:93\u20136.","journal-title":"Rheumatol (Oxf)"},{"key":"290_CR66","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/jdv.13024","volume":"29","author":"C De Simone","year":"2015","unstructured":"De Simone C, Farina M, Maiorino A, Fanali C, Perino F, Flamini A, et al. TNF-alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients. J Eur Acad Dermatol Venereol. 2015;29:1786\u201390.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"290_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0194693","volume":"13","author":"A Aita","year":"2018","unstructured":"Aita A, Basso D, Ramonda R, Moz S, Lorenzin M, Navaglia F, et al. Genetics in TNF-TNFR pathway: A complex network causing spondyloarthritis and conditioning response to anti-TNF\u03b1 therapy. PLoS One. 2018;13:1\u201317.","journal-title":"PLoS One"},{"key":"290_CR68","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1111\/jdv.15431","volume":"33","author":"MC Ovejero-Benito","year":"2019","unstructured":"Ovejero-Benito MC, Mu\u00f1oz-Aceituno E, Reolid A, Fisas LH, Llamas-Velasco M, Prieto-P\u00e9rez R, et al. Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis. J Eur Acad Dermatol Venereol. 2019;33:e175\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"290_CR69","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","volume":"57","author":"M Eichelbaum","year":"2006","unstructured":"Eichelbaum M, Ingelman-sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006;57:119\u201337.","journal-title":"Annu Rev Med"},{"key":"290_CR70","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3899\/jrheum.110980","volume":"39","author":"J Ram\u00edrez","year":"2012","unstructured":"Ram\u00edrez J, Fern\u00e1ndez-Sueiro JL, L\u00f3pez-Mej\u00edas R, Montilla C, Arias M, Moll C, et al. FCGR2A\/CD32A and FCGR3A\/CD16A variants and EULAR response to tumor necrosis factor-\u03b1 blockers in psoriatic arthritis: A longitudinal study with 6 months of followup. J Rheumatol. 2012;39:1035\u201341.","journal-title":"J Rheumatol"},{"key":"290_CR71","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3109\/03009741003781969","volume":"39","author":"MJ Morales-lara","year":"2010","unstructured":"Morales-lara MJ, Garc\u00eda-sim\u00f3n MS, Pedrero F. Association between the FCGR3A V158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients Association between the FCGR3A V158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients. Scan J Rheumatol. 2010;39:518\u201320.","journal-title":"Scan J Rheumatol"},{"key":"290_CR72","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1136\/ard.2008.096982","volume":"68","author":"JD Ca\u00f1ete","year":"2009","unstructured":"Ca\u00f1ete JD, Su\u00e1rez B, Hern\u00e1ndez MV, Sanmart\u00ed R, Rego I, Celis R, et al. Influence of variants of Fc\u03b3 receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor \u03b1 therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1547\u201352.","journal-title":"Ann Rheum Dis"},{"key":"290_CR73","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jbspin.2012.02.003","volume":"79","author":"MJ Morales-Lara","year":"2012","unstructured":"Morales-Lara MJ, Ca\u00f1ete JD, Torres-Moreno D, Hern\u00e1ndez MV, Pedrero F, Celis R, et al. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Jt Bone Spine. 2012;79:591\u20136.","journal-title":"Jt Bone Spine"},{"key":"290_CR74","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1212\/01.wnl.0000436612.66328.8a","volume":"81","author":"L Ottoboni","year":"2013","unstructured":"Ottoboni L, Frohlich IY, Lee M, Healy BC, Keenan BT, Xia Z, et al. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology 2013;81:1891\u20139.","journal-title":"Neurology"},{"key":"290_CR75","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1172\/JCI119616","volume":"100","author":"J Wu","year":"1997","unstructured":"Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100:1059\u201370.","journal-title":"J Clin Invest"},{"key":"290_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78866-2","volume":"10","author":"S Rahmati","year":"2020","unstructured":"Rahmati S, O\u2019Rielly DD, Li Q, Codner D, Dohey A, Jenkins K, et al. Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis. Sci Rep. 2020;10:21703.","journal-title":"Sci Rep"},{"key":"290_CR77","first-page":"545","volume":"38","author":"CL Ventola","year":"2013","unstructured":"Ventola CL. Role of pharmacogenomic biomarkers in predicting and improving drug response. P T 2013;38:545\u201351.","journal-title":"P T"},{"key":"290_CR78","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41397-018-0040-6","volume":"18","author":"J Massey","year":"2018","unstructured":"Massey J, Plant D, Hyrich K, Morgan AW, Wilson AG, Spiliopoulou A, et al. Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. Pharmacogenomics J. 2018;18:657\u201364.","journal-title":"Pharmacogenomics J"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-022-00290-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-022-00290-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-022-00290-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T22:56:29Z","timestamp":1701212189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-022-00290-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,15]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["290"],"URL":"https:\/\/doi.org\/10.1038\/s41397-022-00290-8","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,15]]},"assertion":[{"value":"12 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JB has received a research grant award from Pfizer and travel bursaries from UCB, Eli Lilly, and Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}